Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT03355560
PHASE2

Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy

Sponsor: Trisha Wise-Draper

View on ClinicalTrials.gov

Summary

The purpose of this research study is to test the safety and efficacy of nivolumab after salvage resection in head and neck cancer in patients that have previously received definitive radiation with or without chemotherapy.

Official title: A Single Arm Phase 2 Study of Adjuvant Nivolumab After Salvage Resection in Head and Neck Squamous Cell Carcinoma Patients Previously Treated With Definitive Therapy

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

39

Start Date

2017-12-06

Completion Date

2024-07

Last Updated

2024-02-28

Healthy Volunteers

No

Interventions

DRUG

Nivolumab

Nivolumab 480 mg IV infusion

Locations (2)

Karmanos Cancer Institute

Detroit, Michigan, United States

UC Health

Cincinnati, Ohio, United States